Trans-arterial Chemoembolization Combined with Jinlong Capsule for Advanced Hepatocellular Carcinoma: a PRISMA-compliant Meta-analysis in a Chinese Population

Overview

Journal Pharm Biol

Specialties Pharmacology
Pharmacy

Date 2020 Aug 10

PMID 32767901

Citations 7

Authors

Shuzhao Jia

Ying Fu

Huimin Tao

Affiliations

Soon will be listed here.

Abstract

Context: Jinlong capsule (JLC) is an animal-derived traditional Chinese medical preparation for advanced hepatocellular carcinoma (HCC). However, its clinical efficacy is still not well investigated.

Objective: This study summarizes the efficacy and safety of JLC combined with trans-arterial chemoembolization (TACE) for patients with HCC.

Methods: The databases PubMed, Cochrane Library, Web of Science, EMBASE, Medline, China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journal Database and Chinese Biological Medicine Database were systematically searched from the date of their inception until February 2020. Jinlong capsule, trans-arterial chemoembolization, and hepatocellular carcinoma were the key terms searched. Randomized controlled trials and high-quality prospective cohort trials comparing the combined use of JLC and TACE versus TACE for HCC were included. Data were pooled using random or fixed effect models depending on heterogeneity.

Results: Data from 19 articles with 1,725 HCC patients were analysed. Compared with TACE treatment alone, the combination of TACE and JLC significantly prolonged patients' 6-36 month overall survival ( < 0.05), and markedly improved the overall response rate (RR = 1.37, 95% CI = 1.24-1.52, < 0.00001) and disease control rate (RR = 1.11, 95% CI = 1.06-1.17, < 0.0001) of patients. The liver function, quality of life, and immune function of patients were significantly improved; the partial adverse events related to TACE were also effectively relieved after the combination treatment.

Conclusion: This meta-analysis suggests that the combination of TACE and JLC is more effective in the treatment of HCC than treatment with TACE alone.

Citing Articles

Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer: A systematic review and meta-analysis.

Yu H, Hu J, Han B, Du Y, Chen S, Chen X PLoS One. 2024; 19(11):e0313443.

PMID: 39576764 PMC: 11584121. DOI: 10.1371/journal.pone.0313443.

Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.

Wu J, Tang G, Cheng C, Yeerken R, Chan Y, Fu Z Mol Cancer. 2024; 23(1):218.

PMID: 39354529 PMC: 11443773. DOI: 10.1186/s12943-024-02136-2.

Effectiveness of adjuvant traditional Chinese medicine on macrovascular invasion in patients with hepatocellular carcinoma: a real-world propensity score-matched study.

Yan H, Wang X, Yu L, Liu X, Yan F, Xie Y Front Pharmacol. 2024; 15:1353720.

PMID: 38464727 PMC: 10923102. DOI: 10.3389/fphar.2024.1353720.

Impact of Traditional Chinese Medicine on Prognosis of Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.

Yuan H, Niu Q, Shang X, Zhang L, Li L, Yang H Integr Cancer Ther. 2023; 22:15347354231170536.

PMID: 37395564 PMC: 10328175. DOI: 10.1177/15347354231170536.

Observational studies of traditional Chinese medicine may provide evidence nearly consistent with the randomized controlled trials: A meta-epidemiological study.

Song H, Li N, Yang W, Wu M, Liao X, Zhang Y Integr Med Res. 2022; 11(4):100889.

PMID: 36345486 PMC: 9636547. DOI: 10.1016/j.imr.2022.100889.

References

Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A . Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008; 103(4):914-21. DOI: 10.1111/j.1572-0241.2007.01712.x. View

Li Y, Hu J, Huang H, He Y . Effect of Jinlong capsule on proliferation and apoptosis of human pancreatic cancer cells BxPC-3. J Tradit Chin Med. 2013; 33(2):205-10. DOI: 10.1016/s0254-6272(13)60126-0. View

Jackson D, White I, Riley R . Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012; 31(29):3805-20. PMC: 3546377. DOI: 10.1002/sim.5453. View

Cabrera R, Pannu D, Caridi J, Firpi R, Soldevila-Pico C, Morelli G . The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011; 34(2):205-13. PMC: 3807574. DOI: 10.1111/j.1365-2036.2011.04697.x. View

Shi L, Lin L . The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore). 2019; 98(23):e15987. PMC: 6571372. DOI: 10.1097/MD.0000000000015987. View

Fan W, Wu Y, Lu M, Yao W, Cui W, Zhao Y . A meta-analysis of the efficacy and safety of iodine [I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2018; 43(4):451-459. DOI: 10.1016/j.clinre.2018.09.006. View

Wu G, Zhang L, Li T, Chen J, Yu G, Li J . Short-term effect of combined therapy with Jinlong Capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression. Chin J Integr Med. 2010; 16(2):109-13. DOI: 10.1007/s11655-010-0109-9. View

Wong R, Ahmed A, Gish R . Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015; 19(2):309-23. DOI: 10.1016/j.cld.2015.01.005. View

George B, Aban I . An application of meta-analysis based on DerSimonian and Laird method. J Nucl Cardiol. 2015; 23(4):690-2. DOI: 10.1007/s12350-015-0249-6. View

10.

Li D, Ni T, Tao L, Jin F, Wang H, Feng J . Jinlong Capsule (JLC) inhibits proliferation and induces apoptosis in human gastric cancer cells in vivo and in vitro. Biomed Pharmacother. 2018; 107:738-745. DOI: 10.1016/j.biopha.2018.08.049. View

11.

Lin L, Chu H . Quantifying publication bias in meta-analysis. Biometrics. 2017; 74(3):785-794. PMC: 5953768. DOI: 10.1111/biom.12817. View

12.

Zhu Y, Cui P, Yao J, Zhang Z, Yang J . Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy. Gastroenterol Res Pract. 2018; 2018:6414759. PMC: 5902052. DOI: 10.1155/2018/6414759. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

15.

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

16.

He C, Peng W, Liu X, Li C, Li X, Wen T . Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2019; 98(31):e16557. PMC: 6709300. DOI: 10.1097/MD.0000000000016557. View

17.

Zhang H, Yang J, Wang W, Jiang X, Mao Y, Yang C . [Effects of Jinlong Capsule on expressions of interleukin-2 and soluble interleukin-2 receptor in patients with primary liver cancer after transarterial chemoembolization therapy]. Zhong Xi Yi Jie He Xue Bao. 2008; 6(9):907-10. DOI: 10.3736/jcim20080906. View

18.

Kim D, Han K . Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int. 2016; 10(6):883-892. DOI: 10.1007/s12072-016-9722-9. View

19.

Zhou Z, Liu L, Chen W, Men Z, Lin J, Chen Z . Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol. 2006; 80(951):194-201. DOI: 10.1259/bjr/33521596. View

20.

Panic N, Leoncini E, De Belvis G, Ricciardi W, Boccia S . Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 2014; 8(12):e83138. PMC: 3873291. DOI: 10.1371/journal.pone.0083138. View